#Canada #Vancouver #Debentures #BioVaxys #BioV

BioVaxys Technology Corp. Announces Conversion of Debentures

BioVaxys Technology Corp. (CSE: BIOV) has announced a pivotal financial move involving the conversion of its outstanding unsecured convertible debentures. This decision is the result of notices of conversion received from several debenture holders, signaling confidence in the company's financial health and future prospects.

On September 15, 2025, BioVaxys issued debentures totaling $335,670, which holders can convert into common shares at their discretion, based on the closing price on the Canadian Securities Exchange (CSE) at the time of conversion. The attractive interest rate at 10% per annum adds further incentive for investors. The recent conversions involved a total principal amount of $125,000, plus accrued interest, culminating in an obligation of $126,438.36, which will now be settled through the issuance of 665,465 shares at a conversion price of $0.19 each.

This conversion exemplifies BioVaxys's strategic outlook on capital management and reflects the company’s ongoing commitment to increase shareholder value. By opting for the conversion of these debentures, the company not only manages its debt obligations but also reinforces its capitalization structure, enhancing liquidity while providing shareholders with potential equity upside. Regulatory approvals, such as acceptance from the CSE, are imperative for the issuance of these shares, underscoring the importance of compliance in financial transactions.

About BioVaxys Technology Corp.

Founded in British Columbia, Canada, BioVaxys Technology Corp. is dedicated to the development of novel biopharmaceutical products designed to improve patient outcomes through innovative immunotherapies. The firm leverages the DPX™ immune-educating technology platform and its proprietary HapTenix© tumor cell construct for treating various forms of cancer and immunological diseases. Currently, their clinical pipeline includes promising candidates such as maveropepimut-S (MVP-S), aimed at treating advanced cancers like Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant Ovarian Cancer.

The company's commitment to research and development ensures that it stays at the forefront of biopharmaceutical innovation. With multiple projects in various stages of clinical trials, BioVaxys is poised to make significant impacts in the realm of immunotherapeutics, underlined by data showing MVP-S's ability to activate a robust immune response specifically targeting survivin, a key cancer antigen.

Additionally, BioVaxys is developing dual-targeted immunotherapies such as DPX™+SurMAGE that aims to address multiple cancer antigens simultaneously, further strengthening their position in the competitive landscape of cancer treatment. The company also addresses other pressing health issues, with projects like DPX-RTS for Respiratory Syncytial Virus and BVX-0918, a personalized immunotherapy for late-stage ovarian cancer.

In light of these advancements, BioVaxys shares are publicly traded under the symbol